Concepts (93)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiphospholipid Syndrome | 6 | 2026 | 18 | 3.890 |
Why?
|
| Antibodies, Antiphospholipid | 6 | 2026 | 12 | 2.810 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2022 | 183 | 0.960 |
Why?
|
| Thrombophilia | 1 | 2020 | 14 | 0.660 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 154 | 0.630 |
Why?
|
| Cat-Scratch Disease | 1 | 2019 | 3 | 0.610 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2019 | 10 | 0.610 |
Why?
|
| Sweet Syndrome | 1 | 2019 | 7 | 0.610 |
Why?
|
| Prednisone | 1 | 2019 | 83 | 0.600 |
Why?
|
| Sarcoidosis | 1 | 2019 | 33 | 0.590 |
Why?
|
| Lupus Coagulation Inhibitor | 3 | 2023 | 5 | 0.540 |
Why?
|
| Immunoglobulin M | 3 | 2023 | 116 | 0.530 |
Why?
|
| beta 2-Glycoprotein I | 3 | 2023 | 3 | 0.530 |
Why?
|
| Ribs | 1 | 2015 | 6 | 0.460 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2015 | 16 | 0.460 |
Why?
|
| Bone Diseases | 1 | 2015 | 25 | 0.450 |
Why?
|
| Back Pain | 1 | 2015 | 49 | 0.440 |
Why?
|
| Interferon-alpha | 1 | 2013 | 101 | 0.370 |
Why?
|
| Rheumatology | 2 | 2023 | 70 | 0.360 |
Why?
|
| Musculoskeletal Diseases | 2 | 2023 | 105 | 0.350 |
Why?
|
| Antibodies, Anticardiolipin | 2 | 2022 | 3 | 0.350 |
Why?
|
| Autoantibodies | 2 | 2023 | 185 | 0.350 |
Why?
|
| Acetylcholinesterase | 6 | 2011 | 17 | 0.330 |
Why?
|
| Antioxidants | 5 | 2011 | 250 | 0.320 |
Why?
|
| Immunoglobulin G | 2 | 2023 | 466 | 0.320 |
Why?
|
| Antirheumatic Agents | 2 | 2023 | 227 | 0.320 |
Why?
|
| Thrombosis | 2 | 2021 | 206 | 0.290 |
Why?
|
| Cysteine | 4 | 2011 | 108 | 0.290 |
Why?
|
| Ca(2+) Mg(2+)-ATPase | 6 | 2011 | 11 | 0.270 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 6 | 2011 | 23 | 0.270 |
Why?
|
| Humans | 12 | 2026 | 65452 | 0.220 |
Why?
|
| Brain | 6 | 2011 | 1611 | 0.210 |
Why?
|
| Prospective Studies | 2 | 2023 | 3321 | 0.210 |
Why?
|
| Adult | 4 | 2026 | 17457 | 0.210 |
Why?
|
| Autoimmune Diseases | 1 | 2026 | 239 | 0.210 |
Why?
|
| Rheumatic Diseases | 1 | 2023 | 42 | 0.180 |
Why?
|
| Immunoglobulin A | 1 | 2023 | 102 | 0.180 |
Why?
|
| Registries | 1 | 2026 | 929 | 0.180 |
Why?
|
| Bartonella henselae | 1 | 2019 | 3 | 0.150 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 133 | 0.150 |
Why?
|
| Male | 10 | 2026 | 31177 | 0.150 |
Why?
|
| Cross-Sectional Studies | 1 | 2026 | 2721 | 0.140 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 897 | 0.130 |
Why?
|
| Whole Body Imaging | 1 | 2015 | 10 | 0.110 |
Why?
|
| Radionuclide Imaging | 1 | 2015 | 129 | 0.110 |
Why?
|
| Prognosis | 1 | 2019 | 1788 | 0.110 |
Why?
|
| Rats, Wistar | 6 | 2011 | 184 | 0.110 |
Why?
|
| Radiography, Thoracic | 1 | 2015 | 117 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2020 | 2632 | 0.100 |
Why?
|
| Biopsy | 1 | 2015 | 458 | 0.100 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2013 | 54 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 990 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 58 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2019 | 2111 | 0.090 |
Why?
|
| Lupus Nephritis | 1 | 2012 | 37 | 0.090 |
Why?
|
| Rats | 6 | 2011 | 1996 | 0.090 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 381 | 0.080 |
Why?
|
| Neuroprotective Agents | 1 | 2011 | 78 | 0.080 |
Why?
|
| Nickel | 1 | 2011 | 67 | 0.080 |
Why?
|
| Dendritic Cells | 1 | 2013 | 531 | 0.080 |
Why?
|
| Vaccination | 2 | 2023 | 384 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 2492 | 0.080 |
Why?
|
| Thioacetamide | 1 | 2009 | 5 | 0.080 |
Why?
|
| Choline Deficiency | 1 | 2009 | 14 | 0.080 |
Why?
|
| Carcinogens | 1 | 2009 | 33 | 0.080 |
Why?
|
| Brain Chemistry | 1 | 2009 | 76 | 0.070 |
Why?
|
| Brain Diseases, Metabolic | 1 | 2009 | 3 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 734 | 0.070 |
Why?
|
| Lanthanum | 1 | 2008 | 1 | 0.070 |
Why?
|
| Choline | 1 | 2008 | 23 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2019 | 5806 | 0.070 |
Why?
|
| Middle Aged | 1 | 2026 | 18383 | 0.070 |
Why?
|
| Chlorides | 1 | 2008 | 33 | 0.070 |
Why?
|
| Adenosine Triphosphatases | 1 | 2009 | 256 | 0.060 |
Why?
|
| Animals | 7 | 2013 | 21379 | 0.060 |
Why?
|
| Female | 2 | 2026 | 34188 | 0.060 |
Why?
|
| Child | 2 | 2023 | 4620 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2013 | 3155 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2009 | 732 | 0.040 |
Why?
|
| United States | 2 | 2023 | 8148 | 0.040 |
Why?
|
| Time Factors | 2 | 2008 | 3774 | 0.020 |
Why?
|
| Spectrophotometry | 1 | 2008 | 30 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2008 | 47 | 0.020 |
Why?
|
| Manganese Poisoning | 1 | 2008 | 1 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 213 | 0.020 |
Why?
|
| Manganese Compounds | 1 | 2008 | 8 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2009 | 206 | 0.020 |
Why?
|
| Body Weight | 1 | 2009 | 376 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 605 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2009 | 322 | 0.020 |
Why?
|
| Diet | 1 | 2008 | 536 | 0.010 |
Why?
|
| Age Factors | 1 | 2009 | 1591 | 0.010 |
Why?
|
| Aging | 1 | 2008 | 774 | 0.010 |
Why?
|